KH617 / Chengdu Kanghong Pharma - LARVOL DELTA

A phase I study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of KH617 for patients with advanced solid tumors (including diffuse gliomas of adulthood). (ASCO 2026) - "KH617 has shown significantly superior anti-tumor activity compared to the historical mOS in pts with rGBM, while also being well-tolerated."

Clinical • Metastases • P1 data • PK/PD data • Brain Cancer • Diffuse Glioma • Ependymoma • Glioblastoma • Glioma • Oncology • Solid Tumor

The natural compound KH617: A safe and selective therapeutic agent targeting GBM metabolic reprogramming (AACR 2026) - P2 | "Encouraged by KH617's favorable safety profile and promising early anti-tumor activity in patients with recurrent glioma, we are advancing this compound into a Phase II clinical trial for patients with recurrent GBM (NCT07138001). Beyond GBM, ongoing research is exploring the potential of KH617 across a broader spectrum of human tumor types."

Late-breaking abstract • Anaplastic Astrocytoma • Astrocytoma • Glioblastoma • Oncology • PFKFB3

Broad-spectrum antitumor activity of the biosynthetically derived molecule KHN705 (AACR 2026) - P2 | "We previously developed KH617, a small molecule targeting tumor metabolic reprogramming, via biosynthetic technology...KHN705 exhibited comparable efficacy to single-agent chemotherapy across a wide range of human cancer types, including gastric, hepatocellular, lung, and brain cancers, supporting its further development for treating diverse malignancies. In Vitro: IC50 values were determined against 14 human cancer cell lines (acute myeloid leukemia; colorectal cancer [cisplatin- and 5-FU-resistant variants]; lymphoma; bladder cancer; breast cancer; gastric cancer; prostate cancer; endometrial cancer; thyroid cancer; esophageal cancer; cervical cancer; brain cancer; renal cell carcinoma; lung cancer) following a 72-hour incubation...Mice received vehicle or drug (KHN705, paclitaxel, regorafenib, pemetrexed sodium, temozolomide) for durations ranging from 16 to 28 days... We report the first demonstration of KHN705's anti-tumor activity, enabled by our..."

Late-breaking abstract • Acute Myelogenous Leukemia • Bladder Cancer • Brain Cancer • Breast Cancer • Cervical Cancer • Colorectal Cancer • Endometrial Cancer • Esophageal Cancer • Gastric Cancer • Genito-urinary Cancer • Glioblastoma • Hematological Malignancies • Leukemia • Lung Cancer • Lymphoma • Oncology • Prostate Cancer • Renal Cell Carcinoma • Solid Tumor • Thyroid Gland Carcinoma

KH617 API manufacturing: A synthetic biology approach (AACR 2026) - "Recent completion of Phase I study in China demonstrated encouraging data of an expected mOS over 18 months in patients with recurrent glioblastoma. This work supports future clinical research of KH617 which is the only investigational plant derived drug under Phase II clinical trial empowered by synthetic biology."

Late-breaking abstract • Brain Cancer • Glioblastoma • Glioma • Oncology • Solid Tumor

The natural compound KH617 reverses glioblastoma resistance to alkylating agents via MGMT modulation (AACR 2026) - P2 | "Alkylating agents, exemplified by temozolomide (TMZ), remain the standard of care for GBM; however, their efficacy is heavily influenced by O6-methylguanine-DNA methyltransferase (MGMT) expression. Following promising preclinical results and Phase I data showing durable benefit in some patients, a randomized, controlled, open-label, multi-center Phase II clinical study is assessing the efficacy and safety of injectable KH617 in combination with TMZ versus investigator's choice therapy (TPC) or KH617 monotherapy for recurrent GBM, and demonstrates encouraging early efficacy data. KH617, a synthetic biology empowered novel anti-GBM agent, offers a potential new treatment option for patients with TMZ resistance."

Late-breaking abstract • Brain Cancer • Glioblastoma • Oncology • Solid Tumor • MGMT

The natural compound KH617 targets pediatric and adult high-grade gliomas (AACR 2025) - "Integrating robust preclinical data and encouraging early clinical outcomes, KH617 emerges as a promising therapeutic candidate for pediatric and adult HGGs, addressing critical unmet needs in neuro-oncology.Keywords:KH617; Temozolomide; Avastin; Radiation; High-grade gliomas"

Clinical • Late-breaking abstract • Brain Cancer • CNS Tumor • Diffuse Intrinsic Pontine Glioma • Glioblastoma • Glioma • High Grade Glioma • Oncology • Solid Tumor

A phase I study to assess the safety, tolerability, pharmacokinetics and preliminary antitumor activity of KH617 for patients with advanced solid tumors (including diffuse gliomas of adulthood) (ESMO 2025) - P1 | "Conclusions KH617 exhibits a favorable safety profile and preliminary evidence of anti-tumor activity, particularly in patients with recurrent gliomas. The results support further development of KH617."

Clinical • Metastases • P1 data • PK/PD data • Brain Cancer • Glioblastoma • Glioma • Oligodendroglioma • Oncology • Solid Tumor

Phase 2 Clinical Trial of KH617 (clinicaltrials.gov) - P2 | N=60 | Not yet recruiting | Sponsor: Sichuan Honghe Biotechnology Co., Ltd.

Monotherapy • New P2 trial • Brain Cancer • Glioblastoma • Oncology • Solid Tumor

Phase 1 Trial of KH617 (clinicaltrials.gov) - P1 | N=45 | Recruiting | Sponsor: Sichuan Honghe Biotechnology Co., Ltd. | Initiation date: Dec 2023 ➔ Dec 2022

Metastases • Trial initiation date • Oncology • Solid Tumor

Phase 1 Trial of KH617 (clinicaltrials.gov) - P1 | N=45 | Recruiting | Sponsor: Sichuan Honghe Biotechnology Co., Ltd.

Metastases • New P1 trial • Oncology • Solid Tumor